{"entity":{"id":"nct07608159","kind":"trial","name":"Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.","aka":[],"tldr":"A phase 3 trial in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.","summary":"Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC. is a phase 3, randomised interventional study registered as NCT07608159 by Shanghai Pulmonary Hospital, Shanghai, China, with a registry enrolment figure of 201 participants, started 2026-05 and due to reach its primary completion in 2029-05. Interventions recorded: Stereotactic body radiotherapy (SBRT); neoadjuvant immunotherapy; Neoadjuvant Chemotherapy. Conditions listed: Non Small Cell Lung Cancer; Stereotactic Body Radiotherapy; Neoadjuvant Chemoimmunotherapy; Surgery. Primary outcome: 2-year event-free survival rate. Lung eligibility wording from the registry: \"* Previously untreated, pathologically confirmed, resectable or potentially -resectable stage II, IIIA, or IIIB (N2) non-small cell lung cancer according to the 8th edition of the American Joint Committee on Cancer staging system;\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07608159","url":"https://clinicaltrials.gov/study/NCT07608159"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07608159","phase":"3","setting":"A Randomized, Controlled, Multicenter Phase III Clinical Study of Spatially Fractionated Stereotactic Body Radiotherapy Plus Toripalimab and Chemotherapy Versus Toripalimab Plus Chemotherapy in Patients With Resectable or Potentially Resectable Stage II-III Non-Small Cell Lung Cancer","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","enrolled":201,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07608159/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}